Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs keverprazan bismuth-free dual therapy for Helicobacter pylori eradication
ChiCTR2600129861Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Helicobacter pylori infection comparing Vonoprazan + amoxicillin dual therapy with Keverprazan + amoxicillin dual therapy (2 arms). Primary endpoint: Eradication rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
vonoprazankeverprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600129861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129861.